Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?

BJU International

Volumn 101, Issue 7, 2008, Pages 817-821

  Loeb, Stacy ^a   Roehl, Kimberly A ^b   Catalona, William J ^c   Nadler, Robert B ^c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Age; Prostate cancer; Prostate specific antigen velocity; PSA velocity; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; FAMILY HISTORY; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; RACE; RECEIVER OPERATING CHARACTERISTIC; VELOCITY;

ADULT; AGE FACTORS; AGED; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 40449094865     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07501.x     Document Type: Article

References (12)

1. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995 154 : 407 13
2. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993 270 : 860 4
3. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992 267 : 2215 20
4. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
5. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 7
6. Carter HB, Ferrucci L, Kettermann A et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006 98 : 1521 7
7. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994 152 : 1732 6
8. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 2007 177 : 899 902
9. Moul JW, Sun L, Hotaling JM et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007 177 : 499 504
10. Sun L, Moul JW, Hotaling JM et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int 2007 99 : 753 7
11. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006 67 : 316 20
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Available at: http://www.nccn.org/ professionals/physician_gls/PDF/prostate_detection.pdf. Accessed December 2007